Drug Profile
Research programme: T cell immunotherapies - Fate Therapeutics/Juno Therapeutics
Latest Information Update: 28 Jun 2019
Price :
$50
*
At a glance
- Originator Fate Therapeutics; Juno Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 28 Jun 2019 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 06 Mar 2018 Juno Therapeutics has been acquired by Celgene Corporation
- 06 May 2015 Fate Therapeutics and Juno Therapeutics agree to co-develop chimeric antigen receptor (CAR T) and high-affinity T cell receptor (TCR) therapies in USA for Cancer